Clinical Trial Update: Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) [Phase 3]

View source ↗

Summary

Phase 3 trial of meloxicam (Mobic) in juvenile idiopathic arthritis has completed; the update confirms study status but does not provide results in the excerpt.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Mobic (meloxicam)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Arthritis, Juvenile Rheumatoid | Phase 3 | Status: COMPLETED